Background: SIVA is a transcriptional target of p53 that plays a potential role in the development and progression of cancer. In this study, we analyzed SIVA1 and SIVA2 expression, and its association with clinical features and TP53 and MDM2 expression in bone marrow cells from healthy donors and myelodysplastic syndrome (MDS) patients. Methods: Fifty-five untreated patients with MDS and 22 healthy donors were included. Gene expression was evaluated by quantitative PCR. For statistical analysis, Mann-Whitney test, Spearman correlation analysis and Log-rank (Mantel-Cox) were used, as appropriate. A p value <0.05 was considered statistically significant. Results: SIVA1 and SIVA2 transcripts were significantly decreased in bone marrow samples from MDS patients compared to healthy donors, and positively correlated with MDM2 and TP53 expression in MDS patients (all p < 0.05). MDM2 expression was also downregulated in bone marrow samples from MDS patients compared to healthy donors (p < 0.05). However, SIVA1, SIVA2, MDM2 and TP53 expressions did not impact on MDS outcomes. Conclusions: SIVA1 and SIVA2 transcripts are downregulated in bone marrow samples from MDS patients.
Background
Apoptosis resistance and genomic instability are hallmarks of cancer cells [1, 2] . The p53 tumor suppressor protein is a transcription factor that regulates several signaling pathways involved in the cell response to stress, suppressing malignant transformation by cell cycle arrest, DNA repair, induction of apoptosis and initiation of senescence [3] . Deregulation of p53 is a common event in hematological malignancies. In acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), strong p53 protein expression has been associated with TP53 mutations [4] [5] [6] [7] and TP53 mutations have been associated with poor prognosis [8] [9] [10] [11] . In low-risk MDS patients, high p53 protein expression is an independent predictor of transformation into AML [4] .
SIVA is a transcriptional target of p53 that was initially described as a proapoptotic protein and acts on both extrinsic and intrinsic apoptotic pathways [12, 13] . Two alternatively-spliced transcript variants encoding distinct proteins have been described, SIVA1 and SIVA2. MDM2 is a negative regulator of p53 and may modulate the expression of SIVA through regulation of the stability and activation of p73 and E2F1 transcription factors, which represent a p53-independent mechanism of SIVA regulation [13, 14] . SIVA1 binds to BCL2 and BCL-XL, and abrogates their anti-apoptotic activity [15, 16] . SIVA modulates BAX oligomerization, binds to XIAP, and balances NFκB and JNK signaling, promoting apoptosis [17, 18] . In acute lymphoblast leukemia cell lines, both SIVA isoforms play an important role in the apoptotic pathway, induced through CD27 antigen by activation of BID, with a consequent release of cytochrome C and activation of caspases 9 and 3 [19] . In leukemia cell lines, SIVA1 also binds to and inhibits Stathmin 1 activity, preventing tumor growth [20] . In contrast to the tumor suppression functions initially described for SIVA, recent studies indicate that the conditional knockout of SIVA1 reduced tumorigenesis in KRAS-driven lung cancer murine model [21] and high SIVA1 expression was associated with worse survival rates in AML patients [22] . In the present study, we characterized SIVA1 and SIVA2 expressions in healthy controls and MDS patients, and their correlation with clinical features, as well as the expression of SIVA-related genes: TP53 and MDM2.
Methods

Bone marrow samples
Bone marrow samples collected from 55 untreated patients with MDS and 22 healthy donors from related bone marrow transplantation (median age 33 years [range 18-56]) were analyzed. Patient's characteristics are described in Table 1 . The present study was approved by the Ethics Committee of the University of Campinas in accordance with the Helsinki Declaration. Written informed consent was obtained from all healthy donors and MDS patients who participated in this study.
Patients who attended the clinic between 2005 and 2013 and signed the informed consent for the study were included. Diagnosis was made by clinical data, peripheral blood counts, bone marrow (BM) cytology and histology and cytogenetics. Deficiency anemias, autoimmune diseases and viral infections were excluded [23] . The cases were classified by the WHO 2008 criteria and risk stratification was made according to IPSS-R [24] .
Quantitative polymerase chain reaction (qPCR)
Total RNA was obtained from total bone marrow cells, after removal of erythrocytes by hemolysis, using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Genomic DNA was eliminated using DNAse I treatment (Invitrogen). cDNA was obtained from 1 μg of RNA using RevertAid™ First Strand cDNA Synthesis Kit (MBI Fermentas, St. Leon-Rot, Germany). A total of 120 ng of cDNA was used for gene expression analysis by quantitative PCR (qPCR) in the ABI 7500 Sequence Detection System (Applied Biosystem, Foster City, CA, USA) using specific primers for SIVA1, SIVA2, TP53, MDM2 and HPRT1. Primer sequences and concentrations are described in Table 2 . HPRT1 was used as the reference gene. The relative gene expression was calculated using the equation 2 -ΔΔCT [25] . A negative 'No Template Control' was included for each primer pair. The dissociation protocol was performed at the end of each run to check for nonspecific amplification. Three replicas were run on the same plate for each sample.
Statistical analysis
Statistical analyses were performed using GraphPad Prism 5 (GraphPad Software, Inc., San. Diego, CA, USA) or SAS System for windows 9.2 (SAS Institute, Inc., Cary, NC, USA). Mann-Whitney test was used for measured factors; Spearman correlation analysis was used for ranking correlation tests and Log-rank (Mantel-Cox) was used to estimate overall survival (OS) and event free survival (EFS). OS was defined from time of sampling to In MDS cohort, karyotype findings included very low risk: -Y (n = 1), del(11q) (n = 1); low risk: normal (n = 46), intermediate risk: +8 (n = 2); −7 (n = 1), other (n = 3); high risk: 3 abnormalities (n = 0), and very high risk: >3 abnormalities (n = 2) Figure S2 . Spearman correlation analysis showed a significant positive correlation between SIVA1 and SIVA2 expression in normal (r = 0.74, p < 0.0001, Fig. 1c ) and MDS (r = 0.75, p < 0.0001, Fig. 1d ) bone marrow samples, indicating a similar regulation for both isoforms of SIVA in hematopoietic cells. Figure S1 ), and no differences were observed for MDM2 expression (p > 0.05). No difference was observed in MDM2 and TP53 expression when MDS patients were stratified by WHO 2008 classification into RA/RARS/RCMD group vs. RAEB-1/RAEB-2 group (p > 0.05, Additional file 2: Figure S2 ). MDM2 and TP53 expressions were positively correlated with SIVA1 and SIVA2 in bone marrow samples from MDS patients (MDM2/SIVA1: r = 0.39, p = 0.003; MDM2/SIVA2: r = 0.44, p = 0.0007; TP53/SIVA1: r = 0.48, p < 0.002; TP53/SIVA2: r = 0.32, p = 0.02; Figure 2c ). In healthy donors, SIVA1 and SIVA2 expression correlated only with MDM2 expression, but not with TP53 expression (Additional file 3: Figure S3 ). In our cohort of MDS patients, the factors that were significantly associated with EFS and OS were gender, WHO 2008 classification and IPSS-R by univariate analysis. Male gender and RAEB1/2 classification negatively impact on EFS and OS by multivariate analysis (Table 3) .
Discussion
Herein, we analyzed the expression of SIVA1 and SIVA2 in normal and MDS bone marrow samples, and their correlation with MDM2 and TP53 expression. Regarding SIVA expression in MDS, our results are in agreement with a previous microarray study that showed a downregulation of SIVA in bone marrow mononuclear cells from MDS patients, when compared to healthy donors [26] , and provide further evidence of the participation of SIVA in hematological malignancies.
We also observed a downregulation of MDM2 in MDS patients. Pellagatti and colleagues [27] , using microarray analysis, reported that the ATM signaling pathway is Hazard ratios >1 indicate that the first factor has the poorer outcome deregulated in high-risk MDS, which included downregulation of MDM2. The positive correlation between SIVA transcripts and MDM2 may be related to the fact that both genes are transcription targets of p53 [13, 28] , suggesting a defective transcriptional activity of p53 protein.
SIVA1 binds to and regulates p53 stability by acting as an adapter protein between p53 and MDM2 [29, 30] , and SIVA1 acts as an ubiquitin ligase for ARF and indirectly regulates p53 stability [31] . Given that there is a reduced expression of SIVA1 in bone marrow samples from MDS, herein identified, further studies are necessary to verify whether SIVA1 downregulation may be involved in aberrant p53 signaling pathway reported in MDS cells [32] .
Conclusion
In conclusion, we demonstrated that SIVA expression is impaired in MDS. The downregulation of SIVA and its correlation with MDM2 may be due to defective p53 transcriptional machinery in this disease. Future studies are necessary to verify the effects of SIVA in hematopoietic cells and their participation in the malignant phenotype.
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